{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:58:22Z","timestamp":1747166302337,"version":"3.40.5"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","journalofsurgicalresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Research"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jss.2016.04.025","type":"journal-article","created":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T05:26:23Z","timestamp":1462080383000},"page":"228-231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vacca pox to pexa vec: John Hunter's and Edward Jenner's contribution to oncolytic virotherapy"],"prefix":"10.1016","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6827-8090","authenticated-orcid":false,"given":"Rajiv V.","family":"Dave","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jss.2016.04.025_bib1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/bmj.2.3068.485","article-title":"What did John Hunter do for medicine? Being the centenary lecture to the Hunterian Society on October 8th, 1919","volume":"2","author":"Keith","year":"1919","journal-title":"Br Med J"},{"key":"10.1016\/j.jss.2016.04.025_bib2","first-page":"266","article-title":"John Hunter to Edward Jenner: a lost letter discovered","volume":"67","author":"Le Fanu","year":"1985","journal-title":"Ann R Coll Surg Engl"},{"key":"10.1016\/j.jss.2016.04.025_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/08998280.2005.11928028","article-title":"Edward Jenner and the history of smallpox and vaccination","volume":"18","author":"Riedel","year":"2005","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"10.1016\/j.jss.2016.04.025_bib4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/014107689008300419","article-title":"The influence of John Hunter's inoculation practice on Edward Jenner's discovery of vaccination against smallpox","volume":"83","author":"Turk","year":"1990","journal-title":"J R Soc Med"},{"year":"1986","series-title":"The Genius of China: 3,000 Years of Science, Discovery and Invention","author":"Temple","key":"10.1016\/j.jss.2016.04.025_bib5"},{"key":"10.1016\/j.jss.2016.04.025_bib6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S1201-9712(98)90096-0","article-title":"The myth of the medical breakthrough: smallpox, vaccination, and Jenner reconsidered","volume":"3","author":"Gross","year":"1998","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jss.2016.04.025_bib7","first-page":"103","article-title":"Remarks upon the introduction of inoculation for smallpox in England","volume":"24","author":"Stearns","year":"1950","journal-title":"Bull Hist Med"},{"key":"10.1016\/j.jss.2016.04.025_bib8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/003693309704200407","article-title":"Edward Jenner and the eradication of smallpox","volume":"42","author":"Willis","year":"1997","journal-title":"Scott Med J"},{"key":"10.1016\/j.jss.2016.04.025_bib9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1017\/S0025727300044008","article-title":"The genesis of Edward Jenner's Inquiry of 1798: a comparison of the two unpublished manuscripts and the published version","volume":"29","author":"Baxby","year":"1985","journal-title":"Med Hist"},{"year":"2005","series-title":"Epidemiology and Prevention of Vaccine-Preventable Diseases (the Pink Book)","author":"Atkinson","key":"10.1016\/j.jss.2016.04.025_bib10"},{"key":"10.1016\/j.jss.2016.04.025_bib11","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.mt.6300108","article-title":"History of oncolytic viruses: genesis to genetic engineering","volume":"15","author":"Kelly","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.jss.2016.04.025_bib12","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1099\/0022-1317-83-3-491","article-title":"Cytolytic viruses as potential anti-cancer agents","volume":"83","author":"Ring","year":"2002","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.jss.2016.04.025_bib13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/00000441-190412740-00001","article-title":"The influence of complicating diseases upon leukaemia","volume":"127","author":"Dock","year":"1904","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jss.2016.04.025_bib14","first-page":"199","article-title":"Contribution to the knowledge of sarcoma","volume":"14","author":"Coley","year":"1891","journal-title":"Ann\u00a0Surg"},{"key":"10.1016\/j.jss.2016.04.025_bib15","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/postgradmedj\/79.938.672","article-title":"Dr William Coley and tumor regression: a place in history or in the future","volume":"79","author":"Hoption Cann","year":"2003","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.jss.2016.04.025_bib16","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S1286-4579(00)01337-X","article-title":"The role of fever in the infected host","volume":"2","author":"Hasday","year":"2000","journal-title":"Microbes Infect"},{"key":"10.1016\/j.jss.2016.04.025_bib17","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2217\/imt.10.32","article-title":"Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer","volume":"2","author":"Alexandroff","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jss.2016.04.025_bib18","first-page":"473","article-title":"Studies in Hodgkin's syndrome; the association of viral hepatitis and Hodgkin's disease; a preliminary report","volume":"9","author":"Hoster","year":"1949","journal-title":"Cancer Res"},{"key":"10.1016\/j.jss.2016.04.025_bib19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/bmj.1.4810.589","article-title":"Effects of glandular fever infection in acute leukaemia","volume":"1","author":"Taylor","year":"1953","journal-title":"Br Med J"},{"key":"10.1016\/j.jss.2016.04.025_bib20","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1002\/1097-0142(197412)34:6<1907::AID-CNCR2820340609>3.0.CO;2-4","article-title":"Treatment of human cancer with mumps virus","volume":"34","author":"Asada","year":"1974","journal-title":"Cancer"},{"key":"10.1016\/j.jss.2016.04.025_bib21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jnci\/djj111","article-title":"China approves world's first oncolytic virus therapy for cancer treatment","volume":"98","author":"Garber","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jss.2016.04.025_bib22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1128\/MMBR.55.1.80-122.1991","article-title":"Poxvirus pathogenesis","volume":"55","author":"Buller","year":"1991","journal-title":"Microbiol Rev"},{"key":"10.1016\/j.jss.2016.04.025_bib23","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ymthe.2006.05.008","article-title":"Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF","volume":"14","author":"Kim","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.jss.2016.04.025_bib24","first-page":"8751","article-title":"Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes","volume":"61","author":"McCart","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.jss.2016.04.025_bib25","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1172\/JCI32727","article-title":"Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963","volume":"117","author":"Thorne","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jss.2016.04.025_bib26","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1158\/0008-5472.CAN-05-1630","article-title":"The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2","volume":"65","author":"Guo","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.jss.2016.04.025_bib27","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/mt.2008.143","article-title":"The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma","volume":"16","author":"Liu","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.jss.2016.04.025_bib28","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1470-2045(08)70107-4","article-title":"Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial","volume":"9","author":"Park","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jss.2016.04.025_bib29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jss.2016.04.025_bib30","first-page":"1532","article-title":"Phase 1b trial of biweekly intravenous pexa-vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus in colorectal cancer","volume":"23","author":"Park","year":"2015","journal-title":"Mol\u00a0Ther"},{"key":"10.1016\/j.jss.2016.04.025_bib31","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nm0697-639","article-title":"ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents","volume":"3","author":"Heise","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.jss.2016.04.025_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1535-6108(03)00170-3","article-title":"Getting oncolytic virus therapies off the ground","volume":"4","author":"Bell","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jss.2016.04.025_bib33","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/nrc1750","article-title":"Recent progress in the battle between oncolytic viruses and tumors","volume":"5","author":"Parato","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jss.2016.04.025_bib34","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.seminoncol.2005.09.007","article-title":"Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects","volume":"32","author":"Thorne","year":"2005","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jss.2016.04.025_bib35","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/89901","article-title":"Replication-selective virotherapy for cancer: biological principles, risk management and future directions","volume":"7","author":"Kirn","year":"2001","journal-title":"Nat Med"}],"container-title":["Journal of Surgical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480416300282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480416300282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T04:27:58Z","timestamp":1718512078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022480416300282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0022480416300282"],"URL":"https:\/\/doi.org\/10.1016\/j.jss.2016.04.025","relation":{},"ISSN":["0022-4804"],"issn-type":[{"type":"print","value":"0022-4804"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vacca pox to pexa vec: John Hunter's and Edward Jenner's contribution to oncolytic virotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Surgical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jss.2016.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}